MUC1 is an attractive target for cancer vaccines as a result of its over-expression and aberrant glycosylation pattern on many tumor cells. However, the low immunogenicity of MUC1 and immune tolerance have limited its application. Herein, we designed MUC1-based tricomponent antitumor vaccines adjuvanted with fibroblast stimulating lipopeptide 1 (FSL-1). Immunological results indicate that the glycosylated tricomponent vaccine candidate has elicited both humoral and cellular immune responses. The induced antibodies could effectively bind to MCF-7. Furthermore, the vaccine exhibited an obvious reduction in tumour burden.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991171 | PMC |
| http://dx.doi.org/10.1039/c9md00254e | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy.
Medchemcomm
December 2019
State Key Laboratory of Medicinal Chemical Biology , College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research , Nankai University, Haihe Education Park, 38 Tongyan Road , Tianjin , 300350 , P. R. China . Email: ; Email:
MUC1 is an attractive target for cancer vaccines as a result of its over-expression and aberrant glycosylation pattern on many tumor cells. However, the low immunogenicity of MUC1 and immune tolerance have limited its application. Herein, we designed MUC1-based tricomponent antitumor vaccines adjuvanted with fibroblast stimulating lipopeptide 1 (FSL-1).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!